Ascorbic acid 50mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Ascorbic acid

Available from:

A A H Pharmaceuticals Ltd

ATC code:

A11GA01

INN (International Name):

Ascorbic acid

Dosage:

50mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 09060301; GTIN: 5025903006688

Patient Information leaflet

Patient Information Lea
f
l
e
t A
S
C
O
R
B
I
C
A
C
I
D
50
M
G
T
AB
L
E
T
S
This medicine will be called Ascorbic Acid
T
a
b
l
e
t
s
in this
l
ea
f
l
e
t
.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START
TAKING THIS MEDICINE.
• Keep this leaflet. You may need to read it again.
• This medicine is only for you. Do not give it to
anyone else to take. It may harm them, even if
their symptoms are the same as yours.
• If you have any further questions, please ask your
doctor or pharmacist.
• If you get any side effects talk to your doctor or
pharmacist. This includes any possible side effects
not listed in this leaflet. See section 4.
IN
THIS
L
E
A
FL
E
T
:
1. What Ascorbic Acid Tablets are and what they a
r
e
used
f
o
r
2. Before you take Ascorbic Acid
T
a
b
l
e
t
s
3. How to take Ascorbic Acid
T
a
b
l
e
t
s
4. Possible side e
ff
e
c
t
s
5. How to store Ascorbic Acid
T
a
b
l
e
t
s
6. Further
i
n
f
o
rm
a
t
io
n
1. WHAT ASCORBIC ACID
TABLETS
ARE
A
ND
WHAT THEY ARE USED
F
O
R
These tablets contain the active ingredient, a
s
c
o
r
b
i
c
acid. Ascorbic acid is the chemical name for
V
i
t
a
m
i
n
C. The tablets can be used to increase the amount
o
f
Vitamin C in the
d
i
e
t
.
Vitamin C Tablets are used to treat patients
wi
t
h
scurvy or they can be used by people who are at
r
i
s
k
of Vitamin C
d
e
f
i
c
i
e
n
c
y
.
2. BEFORE YOU TAKE ASCORBIC ACID
TA
B
LE
T
S
SOME
PEOPLE
MUST NOT
TAKE THESE
T
A
B
L
E
T
S.
DO
NOT TAKE THESE TABLETS
IF
:
•
You know you are allergic to ascorbic acid or to any
of the other ingredients
(
t
h
e
s
e are listed in Section 6
)
•
You suffer from hyperoxaluria
(
e
x
c
e
ss
oxalic acid
i
n
the
ur
i
n
e
)
.
YOU
MUST
BE
ESPECIALLY CAREFUL
IF
:
•
You are pregnant or
b
r
ea
s
t
f
ee
d
i
n
g
.
•
You have an intolerance to some sugars.
T
h
e
s
e
tablets contain lactose and
su
c
r
o
s
e.
If any of the conditions above apply to you,
p
l
ea
s
e
discuss your treatment with your doctor before
t
a
ki
n
g
this
m
e
d
i
c
i
n
e.
TAKING OTHER
M
E
DICINES
Ascorbic Acid Tablets can affect some
o
t

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Ascorbic Acid 50mg Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 50mg of ascorbic acid.
Excipient(s) with known effect
Lactose monohydrate
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Tablet.
White to off-white convex tablets.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Prevention and treatment of scurvy.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults and children over 6 years: _
Prophylactic:
25 – 75 mg daily.
Therapeutic:
Not less than 250mg daily in divided doses. Maximum of
1000mg daily.
_Children under 6 years: _
This unit dosage form is unsuitable for children under 6 years.
_Elderly: _As for other adults. As the dietary intake of vitamin C may
be less in
the elderly, they have greater risk of presenting with vitamin C
deficiency.
Method of administration
For oral administration.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in
section 6.1.
Ascorbic acid should not be given to patients with hyperoxaluria.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Increased intake of ascorbic acid over a prolonged period may result
in an
increased renal clearance of ascorbic acid, and deficiency may result
if the
intake is reduced or withdrawn rapidly (see section 4.8).
Interference with serological testing
Ascorbic acid may interfere with tests and assays for urinary glucose,
giving
false-negative results with methods utilising glucose oxidase with
indicator
(e.g. Labstix, Tes-Tape) and false-positive results with neocuproine
methods.
Estimation of uric acid by phosphotungstate or uricase with copper
reduction
and measurement of creatinine in non-deproteinised serum may also be
affected.
High doses of ascorbic acid may give false-negative readings in faecal
occult
blood tests.
Patients with rare hereditary problems of galactose intolerance, total
lactase
deficiency or glucose-galactose malabsorption should not take this
medicine.
4